|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dembo AJ, Davy M, Stenwig AE, Berle EJ,
Bush RS and Kjorstad K: Prognostic factors in patients with stage I
epithelial ovarian cancer. Obstet Gynecol. 75:263–273.
1990.PubMed/NCBI
|
|
3
|
Permuth-Wey J and Sellers TA: Epidemiology
of ovarian cancer. Methods Mol Biol. 472:413–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kornienko AE, Guenzl PM, Barlow DP and
Pauler FM: Gene regulation by the act of long non-coding RNA
transcription. BMC Biol. 11:592013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Geisler S and Coller J: RNA in unexpected
places: Long non-coding RNA functions in diverse cellular contexts.
Nat Rev Mol Cell Biol. 14:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhan L, Li J and Wei B: Long non-coding
RNAs in ovarian cancer. J Exp Clin Cancer Res. 37:1202018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhong Y, Gao D, He S, Shuai C and Peng S:
Dysregulated expression of long noncoding RNAs in ovarian cancer.
Int J Gynecol Cancer. 26:1564–1570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Yu M and Yang C: YY1-mediated
overexpression of long noncoding RNA MCM3AP-AS1 accelerates
angiogenesis and progression in lung cancer by targeting
miR-340-5p/KPNA4 axis. J Cell Biochem. 121:2258–2267. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Luo C and Zhang G: LncRNA
MCM3AP-AS1 regulates epidermal growth factor receptor and autophagy
to promote hepatocellular carcinoma metastasis by interacting with
miR-455. DNA Cell Biol. 38:857–864. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu
Q, Tong X, Yang W, Xu Q, Huang D and Tu K: A novel lncRNA
MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by
targeting miR-194-5p/FOXA1 axis. Mol Cancer. 18:282019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang M, Jia J, Chen L, Wei B, Guan Q,
Ding Z, Yu J, Pang R and He G: LncRNA MCM3AP-AS1 promotes
proliferation and invasion through regulating miR-211-5p/SPARC axis
in papillary thyroid cancer. Endocrine. 65:318–326. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang C, Zheng J, Xue Y, Yu H, Liu X, Ma J,
Liu L, Wang P, Li Z, Cai H and Liu Y: The effect of
MCM3AP-AS1/miR-211/KLF5/AGGF1 axis regulating glioblastoma
aangiogenesis. Front Mol Neurosci. 10:4372018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang R, Ma Z, Feng L, Yang Y, Tan C, Shi
Q, Lian M, He S, Ma H and Fang J: LncRNA MIR31HG targets HIF1A and
P21 to facilitate head and neck cancer cell proliferation and
tumorigenesis by promoting cell-cycle progression. Mol Cancer.
17:1622018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi H, Shen H, Xu J, Zhao S, Yao S and
Jiang N: MiR-143-3p suppresses the progression of ovarian cancer.
Am J Transl Res. 10:866–874. 2018.PubMed/NCBI
|
|
16
|
Wang JY, Lu AQ and Chen LJ: LncRNAs in
ovarian cancer. Clin Chim Acta. 490:17–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nikpayam E, Tasharrofi B, Sarrafzadeh S
and Ghafouri-Fard S: The role of long non-coding RNAs in ovarian
cancer. Iran Biomed J. 21:3–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan JJ and Tay Y: Noncoding RNA:RNA
regulatory networks in cancer. Int J Mol Sci. 19:E13102018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and
Ma W: ceRNA in cancer: Possible functions and clinical
implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ulitsky I: Interactions between short and
long noncoding RNAs. FEBS Lett. 592:2874–2883. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie F, Li C, Zhang X, Peng W and Wen T:
MiR-143-3p suppresses tumorigenesis in pancreatic ductal
adenocarcinoma by targeting KRAS. Biomed Pharmacother.
119:1094242019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qian Y, Teng Y, Li Y, Lin X, Guan M, Li Y,
Cao X and Gao Y: MiR-143-3p suppresses the progression of nasal
squamous cell carcinoma by targeting Bcl-2 and IGF1R. Biochem
Biophys Res Commun. 518:492–499. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li D, Hu J, Song H, Xu H, Wu C, Zhao B,
Xie D, Wu T, Zhao J and Fang L: miR-143-3p targeting LIM domain
kinase 1 suppresses the progression of triple-negative breast
cancer cells. Am J Transl Res. 9:2276–2285. 2017.PubMed/NCBI
|
|
24
|
Zhang H and Li W: Dysregulation of
micro-143-3p and BALBP1 contributes to the pathogenesis of the
development of ovarian carcinoma. Oncol Rep. 36:3605–3610. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aashaq S, Batool A and Andrabi KI: TAK1
mediates convergence of cellular signals for death and survival.
Apoptosis. 24:3–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Neumann D: Is TAK1 a direct upstream
kinase of AMPK? Int J Mol Sci. 19:E24122018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mukhopadhyay H and Lee NY: Multifaceted
roles of TAK1 signaling in cancer. Oncogene. 39:1402–1413. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kilty I and Jones LH: TAK1 selective
inhibition: State of the art and future opportunities. Future Med
Chem. 7:23–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cai PC, Shi L, Liu VW, Tang HW, Liu IJ,
Leung TH, Chan KK, Yam JW, Yao KM, Ngan HY and Chem DW: Elevated
TAK1 augments tumor growth and metastatic capacities of ovarian
cancer cells through activation of NF-κB signaling. Oncotarget.
5:7549–7562. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ataie-Kachoie P, Badar S, Morris DL and
Pourgholami MH: Minocycline targets the NF-κB nexus through
suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer. Mol
Cancer Res. 11:1279–1291. 2013. View Article : Google Scholar : PubMed/NCBI
|
